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Summary Thirty-three patients with squamous cell carcinoma of the head and neck region were studied
concerning p53 protein expression and mutations in exons 4-9 of the p53 gene using immunohistochemistry,
polymerase chain reaction (PCR)-single strand conformation polymorphism analysis and DNA sequencing.
Immunoreactivity was found in 64% and p53 gene mutations in 39% of the tumours. Thirty-three per cent of
the immunopositive and 50% of the immunonegative tumours were mutated within exons 5-8. In one
immunopositive tumour three variants of deletions were observed. Sequencing of the p53 mutated,
immunonegative tumours revealed four cases with deletions, one case with a transversion resulting in a stop
codon and one case with a splice site mutation which could result in omission of the following exon at
splicing. All mutations in the immunonegative tumours resulted in a truncated p53 protein. No association
between p53 gene status and expression of proliferating cell nuclear antigen (PCNA) or cell proliferation as
judged by in vivo incorporation of the thymidine analogue iododeoxyuridine (IdUrd) was found.
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Overexpression of the p53 protein in tumour cells can be
explained by mutation in the p53 gene or complex formation
of wild-type p53 protein with, for example, oncogene pro-
ducts causing a prolonged half-life ofthe p53 protein (Finlay,
1993; Oliner et al., 1993; Rubio et al., 1993). In squamous
cell carcinoma of the head and neck (SCCHN) p53 muta-
tions are frequent and most often found in exons 5-8, which
are parts of the conserved regions of the gene (Somers et al.,
1992; Caamano et al., 1993). Antibodies against p53 suitable
for immunohistochemical detection in formalin-fixed and
paraffin-embedded material are not able to distinguish
between wild-type and mutant forms of the protein, and
therefore no conclusions about mutation frequency can be
drawn from immunohistochemical analysis ofp53 expression.
Recent studies of large-cell lymphomas and astrocytomas
have pointed out a discrepancy between immunoreactivity for
p53 and presence of mutations in the p53 gene (Cesarman et
al., 1993; Rubio et al., 1993), whereas studies ofoesopjhageal
and bladder cancer indicated a good correlation (Esrig et al.,
1993; Wagata et al., 1993). In oesophageal cancer detectable
levels of p53 protein are closely correlated with the occur-
rence of missense mutations (Bennett et al., 1991).
A convenient technique for studies of gene mutations is
polymerase chain reaction (PCR) in combination with single-
strand conformation polymorphism (SSCP) analysis of the
PCR product (Orita et al., 1991). With the SSCP analysis up
to 95% of all mutations can be detected, even with an
admixture of normal cells of up to 85-90% (Michaud et al.,
1992; Wu et al., 1993). Since various mutations alter the
properties of the protein differently (Finlay, 1993), the site of
p53 mutation is supposed to be of biological and clinical
significance. More than 90% of the mutations in the p53
gene in general are missense mutations, causing a change in
an amino acid and a probable increase in stability of the
protein (Harris, 1993). In a study of preinvasive and invasive
SCCHN the frequency of missense mutations was 72% of all
mutations found (Boyle et al., 1993).
In squamous cell carcinoma in oesophagus nonsense as
well as splice site mutations of the p53 gene have been
reported (Audrezet et al., 1993; Huang et al., 1993; Wagata
et al., 1993). A nonsense mutation causes formation of a
truncated protein usually unreactive with antibodies (Chen et
al., 1994). Splice site mutations have rarely been found in the
p53 gene, but a hereditary splice site mutation in a family
with breast and ovarian cancer has been reported causing
loss of one exon owing to disruption of the splice acceptor
site (Jolly et al., 1994).
The functional and clinical importance of p53 expression
and p53 mutation sites are under study in several tumour
types. In hepatocellular carcinomas p53 protein and mRNA
expression were found to be possible prognostic factors (Hsu
et al., 1993). A significant association between p53 mutations
and high proliferative activity judged by Ki67 antigen
positivity has been described in breast carcinoma (Marchetti
et al., 1993), a tumour type in which p53 mutation has been
suggested as an important prognostic indicator (Thorlacius et
al., 1993).
In a recent immunohistochemical study of p53 expression
in SCCHN, no association between p53 deregulation and cell
proliferation was found (Nylander et al., 1995). However,
since none of the three antibodies used could distinguish
between wild-type and mutated protein, no conclusion could
be drawn about mutation status versus cell proliferation. In
the present study mutations in the p53 gene were determined
in SCCHN using PCR and SSCP analysis and the relation-
ship to immunohistochemical detection ofp53 was evaluated.
These data were further correlated to the expression of pro-
liferating cell nuclear antigen (PCNA) and in vivo incorpora-
tion of the thymidine analogue iododeoxyuridine (IdUrd).
Materials and methods
Materials
The material consisted of 33 formalin-fixed and paraffin-
embedded consecutive samples of primary SCCHN. All
patients had, after informed consent, been given an intra-
venous infusion of IdUrd 2-6h before surgery. The study
was approved by the local ethical committee.
Immunohistochemistry
For immunohistochemical detection of p53, PCNA and
IdUrd the following monoclonal antibodies were used: D07
against p53 (Novocastra Laboratories, Newcastle, UK)
(Vojtesek et al., 1992), PC1O against PCNA (Novocastra)
and anti-IdUrd/BrdUrd (Becton Dickinson Immunocyto-
metry Systems, San Jose, CA, USA). As secondary antibody
an alkaline phosphatase-conjugated rabbit anti mouse was
used (D3314; Dakopatts, Denmark). For all antigen stainings
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a labelling index (LI) was calculated as described previously
(Nylander et al., 1994). The immunohistochemical evaluation
and calculation of LI was performed by one of the authors
(KN). Control calculations of LI showed a mean difference
in intra-observer variation of 1.43% (range 5-10%), which
was not statistically significant.
Extraction ofDNAfromparaffin-embedded samples
On paraffin-embedded blocks of SCCHN as much normal
tissue as possible was scraped off with a scalpel. Depending
on the size of the tumour, two or three 10-gLm sections were
cut from each sample. DNA was extracted according to
Shibata (1992). In brief, sections were dewaxed in a series of
xylene and ethanol and dried in a Speedvac (Savant Speedvac
Plus, SC 1 A). Extraction buffer consisting of 100 mM
Tris-HCI and 1 mM EDTA, pH 8.0, was added together
with proteinase K at a concentration of400jig ml- '. Samples
were incubated overnight at 37°C, and the following day
boiled for 7 min and centrifuged, whereafter DNA was found
in the supernatant.
Primers
Exons 4-9 of the p53 gene were amplified from each tumour
using the following primers. For exons 5-9 see Gaidano et
al. (1991), and for exon 4:
P4-5 5'-TGCTCTTTTCACCCATCTAC-3' and
P4-3 5'ATTGAAGTCTCATGGAAGCC-3'
All primers were obtained from Scandinavian Gene Synthesis
(K6ping, Sweden).
PCR and SSCP analysis
Each PCR consisted of 1-21l of the extracted DNA solu-
tion (DNA content not determined by spectrophotometry),
2.5 tLM dNTPs, 10 pmol of each primer, 1 ftCi of [a-32P]dCTP
(Amersham International, Buckinghamshire, UK), 1 x Taq
polymerase buffer, 1 mM magnesium chloride, 0.5 U of Taq
polymerase (all from Promega, Madison, WI, USA). The
total reaction volume was 10 ,l. After a 'hot start' at 94°C
for 10 min, 35 cycles with denaturation at 94°C for 30s,
annealing at 55'C for 1 min and extension at 72'C for 1 min
were performed using a progammable thermal controller,
PTC-100 (MJ Research, Watertown, MA, USA). The PCR
was finished at 72'C for 10min. A 2yl aliquot of the re-
action mixture was diluted with 50 l of 0.1% SDS/lOmM
EDTA and 521 l of 98% formamide, 0.05% bromphenol
blue, 0.05% xylene cyanol and 20mM sodium hydroxide.
This mixture was heated at 95'C for 5 min and chilled on ice,
whereafter 3-5 lal was loaded in each lane of a 6% poly-
acrylamide/TBE gel with 10% glycerol. Gels were run at
room temperature at 3 W for 16-20h, and autoradiography
performed at - 70°C for 4-72 h.
Sequencing ofPCRproducts
The p53-immunonegative tumours found to be mutated by
PCR-SSCP analysis were subjected to sequence analysis to
determine the precise mutation in each case. A new 'non-
radioactive PCR reaction with a higher concentration of
dNTPs (200lIM) and a total volume of 50 tsl was performed
as described above. For ligation and cloning of the PCR
product, a pGEM-T Vector System (Promega) was used with
a 1:1 molar ratio of insert-vector.
At least 16 clones from each tumour were first analysed by
PCR-SSCP, and then a minimum of two clones showing the
same mutation as was found in the initial PCR-SSCP
analysis were sequenced. Following plasmid preparation
dideoxy sequencing of both strands was performed using the
Sequenase Rapid Well DNA Sequencing Kit (USB, Cleve-
land, OH, USA). Samples were run on a 6% polyacrylamide
gel containing 7 M urea at 65 W.
Statistical analysis
For comparing mutational and immunohistochemical data to
LIs for IdUrd, the Mann-Whitney U-test and Kruskal-
Wallis test were used.
Results
Immunohistochemistry
Twenty-one of the 33 tumours (64%) showed a distinct
nuclear staining with the p53 antibody D07, with a median
LI of 48% (range 11-85%). All tumours were positively
stained with the antibodies against PCNA and IdUrd.
Median LI for PCNA was 61% (range 23-90%) and for
IdUrd 11% (range 3-40%) (Nylander et al., 1995).
Table I Characterisation of the 13 p53 mutated tumours showing tumour localisation,
median values for p53, PCNA and IdUrd as well as site and type of mutation
Mutation
Localisation p53a PCNAa IdUrd Exon Type
Gingiva 61 80 24 5
Gingiva 83 80 17 7
Gingiva 33 40 12 6
Tonsil 36 54 11 5,6,7
Tonsil 11 65 8 6
Hypopharynx 60 48 7 5
Larynx 74 64 16 5,8
Tongue TI 0 30 10 8 Del GAATCTCCGCAAGAb
codon 287-292
Larynx T2 0 76 18 8 Del AGCTb
codon 269,270
Larynx T3 0 65 19 8 Transversion G-*Tb
codon 271
Larynx T4 0 93 14 7 Del Gb codon 249
Del CTb codon 227
Del G codon 249+del CT
codon 227.
Bucca T5 0 61 17 7 Del ACb
codon 231
Hypopharynx 0 48 8 Intron 5 Splice site mutationc
T6 g+t
'LI (per cent positive cells). bCausing formation of stop codons. cCausing omission of
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Figure 1 SSCP analysis of exon 8 of the p53 gene showing
mutations in one immunonegative (tumour TI in Table I) and
one immunopositive tumour.
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PCR and SSCP analysis
Amplification of exons 5-8 was accomplished in 95% of the
reactions, and of exon 4 in 70% of the tumours.
Sixteen mutations were found in 13 of the 33 tumours
(39%). Ten of these mutations were demonstrated in 7 of the
21 p53-immunopositive tumours, meaning that 33% of the
immunopositive and 50% of the immunonegative tumours (6
out of 12) were mutated as judged by the SSCP analysis.
Two of the immunopositive tumours showed more than one
mutation: one tumour had mutations in exons 5, 6 and 7 and
the other tumour had mutations in exons 5 and 8 (Table
I).
Twelve of the 16 mutations (75%) were located in exons 5,
7 and 8 encoding for parts of the five evolutionarily con-
served p53 domains. Exon 5 mutations (four cases) were
restricted to the immunopositive tumours. The remaining
mutations were found in exon 6.
Since 6 of the 12 immunohistochemically negative tumours
were shown to be mutated by PCR/SSCP (Figure 1), these
cases were further studied by sequence analysis in order to
determine the type of mutation in each case.
Sequence analysis
All data for the sequenced samples are shown in Table I and
Figure 2.
Four of the tumours showed frameshift deletions. In one
of these tumours, 14 bases in exon 8 were missing, and in
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Figure 2 Sequencing data for tumour TI -T6.
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another tumour two deletions and a combination of these
were demonstrated to be distributed in different bacterial
clones (Table I), all causing formation of stop codons. A fifth
tumour showed transversion of G->T, turning the mutated
codon into a stop codon.
The last tumour showed a splice site mutation in which the
last base (g) in the splice acceptor site of intron 5 was
transversed to a t. Theoretically this means inhibition of
normal splicing (Lewin, 1990) causing omission of exon 6 in
the mRNA. Because of this omission, a frameshift occurs,
introducing a stop codon in exon 7. Unfortunately, no fur-
ther tissue was available for RNA analysis.
Comparison ofimmunohistochemical and mutation datafor
pS3 with LI/PCNA andLI/IdUrd
When comparing mutated with non-mutated tumours and
immunopositive with immunonegative tumours no difference
was found in LI/PCNA or in LI/IdUrd. (Table II).
Table H Subgrouping of all 33 tumours based on data from
immunohistochemical analysis (p53 IHC), mutation analysis (p53
mutation) and a combination ofimmunohistochemical and mutation
analysis (p53 IHC/mutation). Median values for p53, PCNA and
IdUrd are given for each group. P-values were calculated by
statistical analysis of LIs for IdUrd in each group
p53a PCNAa IdUrd' No P-valueb
pS3 IHCU
+ 48 (11-83) 65 (25-86) 11 (4-40) 21 0985
- - 56 (23-93) 13 (3-19) 12
p53 mutation
+ 60 (11-83) 64 (30-93) 14 (7-24) 13
(seven tumours) 0.427 - 46 (15-70) 57 (23-86) 10 (3-40) 20
(14 tumours)
p53 IHCUlmutation
+/+ 60 (11-83) 64 (40-80) 12 (7-24) 7
+/- 46 (15-70) 65 (25-86) 10 (4-40) 14
-/+ - 63 (30-93) 16 (8-19) 6 0788
/I- - 48 (23-70) 11 (3-18) 6
All 48 (11-83) 61 (23-93) 11 (3-40) 33
aMedian LI; range shown in brackets. bThe statistical data shown
refer to the IdUrd values. Clmmunohistochemistry.
Discussion
In the present study mutations in the p53 gene were com-
pared with immunohistochemical p53 protein expression in
the same tumours. Immunopositivity was found in 64%,
which is in the range found in earlier studies of SCCHN
(Bennett et al., 1991; Field et al., 1991; Caamano et al.,
1993). A discrepancy existed concerning immunoreactivity
and PCR-SSCP results with 39% of p53 mutated cases
evenly distributed between immunopositive and immuno-
negative tumours. Similar data have been published for large-
cell lymphomas, astrocytomas and different cell lines
(Wynford-Thomas, 1992; Cesarman et al., 1993; Rubio et al.,
1993). One explanation for this discrepancy could be that
immunopositive but SSCP-negative tumours had mutations
outside the exons studied (exons 4-9), leading to a prolonged
p53 protein half-life. However, only a small percentage of
mutations in SCCHN has been found outside exons 5-8
(Boyle et al., 1993). A more probable explanation is that
these tumours harboured excessive amounts of wild-type p53
retained by binding to other proteins (Finlay, 1993; Rubio et
al., 1993). The finding that all tumours with mutation in
exon 5 were immunopositive could be explained by the fact
that different mutations in the p53 gene alter properties of
the protein differently, and mutation in exon 5 causes an
approximate 5- to 12-fold increase in protein half-life com-
pared with the wild-type p53 protein (Finlay, 1993).
To enable detection of mutations, tumour tissue should
constitute at least 10-15% of the total tissue sample (Wu et
al., 1993). In our material most of the adjacent normal tissue
was removed before preparation of DNA, in order to reduce
the risk of concealing tumour tissue. Using the SSCP techni-
que, up to 95% of all mutations are found, which is another
factor to take into account in the evaluation (Michaud et al.,
1992).
Missense mutations in the p53 gene cause an increase in
protein stability, and it is logical that no such mutation was
found among the immunonegative tumours. Instead these
tumours contained four cases with deletions which, in accor-
dance with earlier findings in immunonegative tumours
(Chen et al., 1994), caused frameshifts and formation of stop
codons. These data also explain the discrepancy between
immunonegativity and presence ofmutations, since the muta-
tions found resulted in a truncated p53 protein unreactive
with the antibody used. It cannot be excluded that some of
the immunopositive tumours also had mutations causing
frameshifts and formation of stop codons and that the posi-
tive staining reaction was due to the presence of wild-type
p53 protein. Considering data from other studies of p53 gene
mutations in human cancers, nonsense and frameshift muta-
tions, however, constitute only 5.5% of all p53 mutations
studied (Levine et al., 1994).
A case with splice site mutation, to our knowledge only
reported once before in SCCHN (Boyle et al., 1993), was also
found. Transversions affecting the splice site consensus
sequence have been reported in oesophageal and breast
cancer (Audrezet et al., 1993; Jolly et al., 1994). Theo-
retically, such a mutation causes omission of a whole exon
and introduction of a stop codon in the following exon, as
shown by Jolly et al. (1994) in a family with hereditary
breast-ovarian cancer.
The finding of mutations in three different exons in one of
the immunopositive tumours is also interesting. Mutations in
two exons in the same SCCHN tumour have been reported
previously (Boyle et al., 1993). Our tumour with three
mutated exons was a tonsillar cancer with similar characteris-
tics as the other tumours in the study.
The impact of p53 protein status on tumour cell prolifera-
tion can be assessed by comparison with the expression of
known proliferation markers. One marker often used is
PCNA, which in certain cell lines, e.g. of cervical epithelial
origin, is transcriptionally unaffected by p53 (Mack et al.,
1993). The opposite has been found in a human glioblastoma
cell line, in which induction of wild-type p53 was accom-
panied by a down-regulation in PCNA expression (Mercer et
al., 1991). In the present study no obvious connection
between PCNA expression and p53 mutations was found,
and an effect of the p53 protein on PCNA regulation cannot
be excluded. The reliability of PCNA as a cell proliferation
marker has lately been questioned, since PCNA-positive cells
have been observed in areas with no obvious cell prolifera-
tion (McCormick and Hall, 1992).
In vivo labelling with the thymidine analogue IdUrd can
give an indication of the 'true' tumour cell proliferation since
it is incorporated in cells actively replicating DNA. The fact
that no difference in LI/IdUrd was found between p53
mutated and non-mutated tumours indicated that p53 did
not exert a measurable effect on tumour cell proliferation.
The clinical importance of mutations in the p53 gene in
SCCHN remains to be explained (Frebourg et al., 1993). It is
well known that carcinogens affect the mutational pattern in
the p53 gene (Habuchi et al., 1993; Perwez Hussain et al.,
1994) and in SCCHN heavy smoking and drinking have been
found to correlate to overexpression of the p53 protein
(Langdon and Partridge, 1992), but no thorough analysis of
epidemiological factors and p53 mutation spectrum has been
performed. We have now initiated a retrospective study
focused on the relationship between different exposure fac-
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